
==== Front
Blood Adv
Blood Adv
Blood Advances
2473-9529
2473-9537
The American Society of Hematology

S2473-9529(24)00413-0
10.1182/bloodadvances.2024013528
Commentary
Interleukin-1β, JAK2V617F mutation and inflammation in MPNs
Hermouet Sylvie sylvie.hermouet@univ-nantes.fr
12∗
Hasselbalch Hans C. 34
1 Nantes Université, INSERM, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302, Nantes, France
2 Laboratoire d’Hématologie, CHU Nantes, Nantes, France
3 Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
4 Department of Hematology, Zealand University Hospital, Roskilde, Denmark
∗ Correspondence: Sylvie Hermouet, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302, Institut de Recherche en Santé 2, Université de Nantes, 22 Blvd Benoni Goullin, F-44000 Nantes, France; sylvie.hermouet@univ-nantes.fr
14 7 2024
27 8 2024
14 7 2024
8 16 43444347
30 4 2024
16 6 2024
© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
2024
The American Society of Hematology
https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
==== Body
pmcTO THE EDITOR:

Long before the discovery of the JAK2, CALR, and MPL mutations, chronic inflammation was an established characteristic of BCR-ABL–negative myeloproliferative neoplasms (MPNs). Numerous studies showed that various conditions of chronic inflammation could precede and facilitate the development of all subtypes of MPNs. A nonexhaustive list of such conditions includes inflammatory bowel diseases, inflammatory rheumatic or autoimmune diseases, obesity, diabetes mellitus and not least, cigarette smoking.1, 2, 3, 4, 5, 6, 7 Cellular sources of production of proinflammatory cytokines include hematopoietic progenitors, especially megakaryocytes, typically mutated in MPNs, but also T-lymphocytes and endothelial cells, rarely mutated in MPNs, and stromal cells, which remain wild-type. The extent to which MPN-driver mutations contribute to the high level of inflammation characteristic of MPNs remains debated.2,3,8

In a recent and elegant study, Rai et al extensively studied the role of a major inflammatory cytokine, interleukin-1β (IL-1β), in murine models combining conditional JAK2V617F-induced MPN and knockout of either IL-1β or IL-1 receptor 1 (IL-1R1).9 Rai et al demonstrated that both IL-1β and IL-1R1 are required by JAK2V617F-mutated hematopoietic cells for optimal MPN disease initiation and expansion. Importantly, they also showed that in vivo inhibition of IL-1β (using a neutralizing anti–IL-1β antibody), reduces disease initiation of JAK2V617F-induced MPN in mice. Their parallel studies of patients with MPN show that 2 IL-1β gene polymorphisms associated with increased IL-1β levels are more frequent in patients with JAK2V617F-mutated MPN than in healthy controls.9 Rai et al also studied cellular sources of production of IL-1β in mice and show that megakaryocytes and monocytes produce more IL-1β in JAK2V617F-expressing mice than in wild-type JAK2 mice.9 Altogether, the data imply that the expansion of clonal hematopoiesis of indeterminate potential (CHIP) with JAK2V617F mutation is facilitated by and dependent on IL-1β. Rai et al concluded that IL-1β produced by JAK2V617F-mutated cells induces an inflammatory bone marrow environment that promotes the expansion of JAK2V617F-mutated cells and the conversion to MPN, and that consequently, IL-1β inhibition could be beneficial to individuals with JAK2V617F CHIP.9

IL-1β is indeed an interesting target in MPNs, not only to prevent or slow the expansion of JAK2V617F-mutated clones when they are still minor, but also to reduce myelofibrosis in established MPNs, as recently reported in mice with JAK2V617F-driven MPN.10, 11, 12 Yet Rai et al provide new and important information about just 1 arm of the complex story of chronic immune stimulation and inflammation in MPNs. In the pathogenic model they propose, the principal inflammatory culprit is IL-1β, and the JAK2V617F mutation is responsible for the excess of IL-1β.9 In fact, the association between inflammation and the MPNs is more complex.1, 2, 3,8,13,14 IL-1 is clearly a major contributor to chronic inflammation, capable of stimulating the production of numerous cytokines and chemokines, by various cell types, both wild-type cells and eventually mutated cells in individuals with an MPN. A major inhibitor of IL-1 production, acting on different cell types, is interferon alpha (IFN-α). There is renewed interest in IFN-α treatment, which we have known for over 40 years to be effective in both solid and blood malignancies, including MPNs, both JAK2- or CALR-mutated.15, 16, 17, 18 Thus, owing to its many anticancer effects and being an important regulator of inflammation, angiogenesis and fibrosis, IFN-α has been used with efficacy for the treatment of hairy cell leukemia, chronic myelogenous leukemia, lymphoma, multiple myeloma, and BCR-ABL–negative MPNs. Decades ago, several groups reported the potential impact of IL-1β inhibition in blood malignancies. For instance, IL-1β could be antagonized with the IL-1 soluble receptor or IL-1 receptor antagonists, shown to be additive with IFN-α in suppressing chronic myelogenous leukemia precursor cells.19,20

In the different pathological contexts described above, obviously the chronic excess of IL-1β cannot be explained solely by the JAK2V617F mutation, because IL-1β is also elevated in patients with CALR- or MPL-mutated MPNs.21 Rather, IL-1β overproduction is likely caused by a combination of chronic, pathological proinflammatory mechanisms that precede CHIP and the development of blood malignancy and, directly or indirectly, various genetic alterations associated with blood malignancy, including the JAK2V617F and CALR mutations in patients with MPN. Thus, in addition to JAK2V617F-dependent IL-1β, we would like to underscore the importance of JAK2V617F-independent and pre-JAK2V617F production of IL-1β, and that IL-1β is also found elevated in patients with CALR- or MPL-mutated MPNs, which was not discussed in the study by Rai et al9

Various chronic inflammatory conditions, congenital or acquired, have been reported by many groups as frequent in the history of patients diagnosed with all subtypes of MPNs. This supports a model where inflammation and subsequent IL-1β overproduction precedes the acquisition of MPN-associated mutations in hematopoietic progenitor cells for subsets, if not all, patients with MPN. The data by Rai et al on certain IL-1β gene polymorphisms being over-represented in patients with MPN support this model. Polymorphisms in other genes, including JAK2 and NF-κB1, have been shown to be associated with chronic inflammation, elevated IL-1β levels, and an increased risk of MPN.22 Inversely, loss-of-function polymorphism in IL6R reduces the risk of JAK2V617F mutation and MPN.23 The efficacy of the pharmaceutical inhibition of the NF-κB cascade, critical in inflammation and notably for the production of IL-1β, is demonstrated in MPNs.24 Importantly, when cytokine production associated with the different MPN subtypes and mutations were analyzed and compared, in patients and in vitro, distinct cytokine profiles were reported depending on the JAK2V617F or CALR mutants but also depending on MPN subtype, that is, polycythemia vera, essential thrombythemia (ET), primary myelofibrosis.21,25 For patients with JAK2V617F-mutated MPN, blood levels of IL-1β and IL-1R1 (IL-1Rα) correlated with the JAK2V617F allelic burden, and in vitro expression of JAK2V617F clearly induced the production of IL-1β, IFN-γ-inducible protein 10 (IP-10, or CXCL10), and RANTES.21 In contrast, the cytokine profiles observed for patients with CALR-mutated ET were characterized by overproduction of tumor growth factor b and several interleukins produced by nonmutated cells (IL-4, IL-9, IL-26, IL-33).21 Notably, in vitro expression of CALR mutants did not induce the production of these cytokines.21 In addition, GRO-α and epidermal growth factor (produced by nonhematopoietic cells) were reported as elevated and markers of disease progression in patients with ET with either JAK2V617F or CALR mutations.26

To summarize, numerous cytokines are overproduced in all subsets of MPNs. CALR mutants do not seem to directly alter cytokine production whereas JAK2V617F clearly increases the expression of IL-1β and IL-1R1. Several cytokines overexpressed in MPNs are produced by nonmutated cells, and it is established that inflammation can precede the acquisition of JAK2/STAT5-activating mutations. For instance, autoimmune disease can cause chronic inflammation and excess of IL-1β, eventually creating a fertile ground for the acquisition of JAK2 or CALR mutations and the development of MPN. In JAK2V617F-mutated MPNs, strongly inflammatory IL-1β induced by JAK2V617F further stimulates cytokine production by both mutated and nonmutated cells. The model of MPN pathogenesis represented in Figure 1 takes into account both mutation-dependent and mutation-independent inflammation and IL-1β production.3,8Figure 1. JAK2V617F-dependent vs mutation-independent IL-1β and inflammation in MPNs. Blood levels of numerous cytokines, including strongly inflammatory IL-1β, are elevated in all subtypes of JAK2-, CALR- or MPL-mutated MPNs. Several cytokines over-expressed in MPNs, including IL-1β, are produced by nonmutated cells, and inflammation may precede the acquisition of JAK2/STAT5-activating mutations. For instance, autoimmune disease can cause chronic inflammation and IL-1β production, eventually leading to the acquisition of JAK2 CALR or MPL mutations and MPN. In vitro studies showed that expression of CALR mutants did not induce cytokine production. In contrast, JAKV617F clearly increases the expression of IL-1R1, IL-1β and IP-10. In JAK2V617F-mutated MPNs, JAK2V617F-induced expression of IL-1β and IL-1R1 further stimulates cytokine production and inflammation, by both the mutated and nonmutated cells in the bone marrow. Inflammation and JAK1- and JAK2V617F-dependent IL-1β production are sensitive to most JAK inhibitors. In contrast, JAK inhibitors have no effect on IL-1β action, since IL-1β does not signal via JAK/STAT. However, IL-1β can be inhibited by IL-1β antagonists, neutralizing anti-IL-1β antibodies, and NF-κB inhibitors. Importantly, IFN-α represses IL-1β and stimulates T-lymphocyte subsets that secrete anti-inflammatory IL-4, and IL-9, a prothrombopoiesis and prothrombosis cytokine.

Hence, given the complexity of inflammation in MPNs, only the integrated analysis of multiple experimental models, both in vitro and in vivo, human and murine, will allow full understanding of its biology and various mechanisms. For instance, mouse models cannot recapitulate the genetic predisposition of patients to acquire MPN, but they can be manipulated experimentally to observe the impact of different stimuli on the selection and expansion of MPN-mutated clones. Patient samples studied at different stages of MPN disease provide unique information, but they also have limitations of their own, particularly a high interindividual variability.

Such an approach is also essential for the therapy of MPNs. To improve treatments, it is important to remember that 3 main pathways are involved in inflammation: the NF-κB, hypoxia inducible factor (HIF ), and JAK1/STAT1 pathways.3 Most JAK inhibitors reduce both JAK1- and JAK2V617F-dependent IL-1β production but have no effect on the action of IL-1β, since this cytokine does not signal via JAK/STAT. The action of IL-1β can be inhibited by IL-1β antagonists, neutralizing anti–IL-1β antibodies and NF-κB inhibitors. Importantly, IFN-α not only represses IL-1β but also stimulates T-cell subsets that secrete anti-inflammatory cytokines.27,28 Ultimately, optimal therapy for MPNs would combine drugs that target JAK2/STAT5-activating mutations (JAK2V617F, CALR, MPL) and inflammation in general, not just IL-1β, as reported for IFN-α2 and ruxolitinib in both clinical and experimental studies.29, 30, 31 The results from these studies together with those of Rai et al call for new studies in patients with MPN on the safety and efficacy of combination therapy with IFN-α2 and neutralizing anti–IL-1β monoclonal antibody therapy.

Conflict-of-interest disclosure: H.C.H. has received a research grant from Novartis A/S; and serves on the advisory board for AOPOrphan and Incyte. S.H. declares no competing financial interests.

Contribution: S.H. wrote the first version of the manuscript; and H.C.H. contributed to the final version of the manuscript.
==== Refs
References

1 Kristinsson SY Landgren O Samuelsson J Björkholm M Goldin LR Autoimmunity and the risk of myeloproliferative neoplasms Haematologica 95 7 2010 1216 1220 20053870
2 Hasselbalch HC Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood 119 14 2012 3219 3225 22318201
3 Hermouet S Bigot-Corbel E Gardie B Pathogenesis of myeloproliferative neoplasms: role and mechanisms of chronic inflammation Mediators Inflamm 2015 2015 145293
4 Pedersen KM Bak M Sørensen AL Smoking is associated with increased risk of myeloproliferative neoplasms: a general population-based cohort study Cancer Med 7 11 2018 5796 5802 30318865
5 Ramanathan G Hoover BM Fleischman AG Impact of host, lifestyle and environmental factors in the pathogenesis of MPN Cancers 12 8 2020 2038 32722135
6 Marnell CS Bick A Natarajan P Clonal hematopoiesis of indeterminate potential (CHIP): linking somatic mutations, hematopoiesis, chronic inflammation and cardio-vascular disease J Mol Cell Cardiol 161 2021 98 105 34298011
7 Pasupuleti SK Ramdas B Burns SS Obesity induced inflammation exacerbates clonal hematopoiesis J Clin Invest 133 11 2023 e163968
8 Hermouet S Mutations, inflammation and phenotype of myeloproliferative neoplasms Front Oncol 13 2023 1196817
9 Rai S Zhang Y Grockowiak E IL-1β promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells Blood Adv 8 5 2024 1234 1249 38207211
10 Arranz L Sánchez-Aguilera A Martín-Pérez D Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms Nature 512 7512 2014 78 81 25043017
11 Rai S Grockowiak E Hansen N Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm Nat Commun 13 1 2022 5346 36100613
12 Rahman MF Yang Y Le BT Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm Nat Commun 13 1 2022 5347 36100596
13 Fleischman AG Aichberger KJ Luty SB TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms Blood 118 24 2011 6392 6398 21860020
14 Fisher DAC Miner CA Engle EK Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling Leukemia 33 8 2019 1978 1995 30718771
15 Newton RC Effect of interferon on the induction of human monocyte secretion of interleukin-1 activity Immunology 56 3 1985 441 449 2416675
16 Silver RT Interferon in the treatment of myeloproliferative diseases Semin Hematol 27 3 suppl 4 1990 6 14 2115694
17 Kiladjian JJ Mesa RA Hoffman R The renaissance of interferon therapy for the treatment of myeloid malignancies Blood 117 18 2011 4706 4715 21389325
18 Verger E Cassinat B Chauveau A Clinical and molecular response to interferon-alpha therapy in essential thrombocythemia patients with CALR mutations Blood 126 24 2015 2585 2591 26486786
19 Estrov Z Kurzrock R Wetzler M Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity Blood 78 6 1991 1476 1484 1715791
20 Dinarello CA Van Der Meer JW Treating inflammation by blocking interleukin-1 in humans Semin Immunol 25 6 2013 469 484 24275598
21 Allain-Maillet S Bosseboeuf A Mennesson N Anti-glucosylsphingosine autoimmunity, JAK2V617F-dependent interleukin-1 and JAK2V617F-independent cytokines in myeloproliferative neoplasms Cancers 12 9 2020 E2446
22 Zhou Y Yan S Liu N Genetic polymorphisms and expression of NLRP3 inflammasome-related genes are associated with Philadelphia chromosome-negative myeloproliferative neoplasms Hum Immunol 81 10-11 2020 606 613 32981742
23 Pedersen KM Colak Y Ellervik C Hasselbalch HC Bojesen SE Nordestgaard BG Loss-of-function polymorphism in IL6R reduces risk of JAK2V617F somatic mutation and myeloproliferative neoplasm: a Mendelian randomization study EClinicalMedicine 21 2020 100280
24 Laranjeira ABA Kong T Snyder SC In vivo ablation of NFκB cascade effectors alleviates disease burden in myeloproliferative neoplasms Blood 143 23 2024 2414 2424 38457657
25 Boissinot M Cleyrat C Vilaine M Jacques Y Corre I Hermouet S Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F Oncogene 30 8 2011 990 1001 21042281
26 Øbro NF Grinfeld J Belmonte M Longitudinal cytokine profiling identifies GRO-α and EGF as potential biomarkers of disease progression in essential thrombocythemia Hemasphere 4 3 2020 e371
27 Mayer-Barber KD Yan B Clash of the cytokine titans: counter-regulation of interleukin-1 and type I interferon-mediated inflammatory responses Cell Mol Immunol 14 1 2017 22 35 27264686
28 Hillyer P Raviv N Gold DM Subtypes of type I IFN differentially enhance cytokine expression by suboptimally stimulated CD4(+) T cells Eur J Immunol 43 12 2013 3197 3208 24030809
29 Sørensen AL Mikkelsen SU Knudsen TA Knudsen TA ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study Haematologica 105 9 2020 2262 2272 33054051
30 Silver RT Combination therapy with interferon and ruxolitinib for polycythemia vera and myelofibrosis: are two drugs better than one? Haematologica 105 9 2020 2190 2191 33054041
31 Austin RJ Straube J Bruedigam C Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations Leukemia 34 4 2020 1075 1089 31732720
